Northera Under FDA Review

Oct 15, 2013

Nasdaq

The Cardiovascular and Renal Drug Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the New Drug Application (NDA) Chelsea Therapeutics International, Ltd. filed for Northera in Jul 2013. The meeting is scheduled to take place on Jan 14, 2014.

Chelsea Therapeutics is looking to get Northera approved for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure). The FDA's decision on the approval of Northera is expected by Feb 14, 2014.Northera has both orphan drug designation and fast track designation in the U.S. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments